Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 8OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Specimen Handling 48Magnetic Resonance Spectroscopy 39Cyclophosphamide 29Vincristine 23Radiation 20Dexamethasone 19Radiotherapy 18Etoposide 18Cisplatin 18Biopsy 18Carboplatin 17Doxorubicin 13Cytarabine 13daratumumab 12Leucovorin 12Methotrexate 11Gemcitabine 11X-Rays 10Standard of Care 10Radiotherapy, Intensity-Modulated 10Platinum 10Docetaxel 10durvalumab 9Rituximab 9Radiotherapy, Conformal 9Prednisone 9Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 90 days × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡